Orally bioavailable Syk inhibitors with activity in a rat PK/PD model.
Thoma, G., Veenstra, S., Strang, R., Blanz, J., Vangrevelinghe, E., Berghausen, J., Lee, C.C., Zerwes, H.G.(2015) Bioorg Med Chem Lett 25: 4642-4647
- PubMed: 26320624 
- DOI: https://doi.org/10.1016/j.bmcl.2015.08.037
- Primary Citation of Related Structures:  
5CXH, 5CXZ, 5CY3 - PubMed Abstract: 
Design and optimization of benzo- and pyrido-thiazoles/isothiazoles are reported leading to the discovery of the potent, orally bioavailable Syk inhibitor 5, which was found to be active in a rat PK/PD model. Compound 5 showed acceptable overall kinase selectivity. However, in addition to Syk it also inhibited Aurora kinase in enzymatic and cellular settings leading to findings in the micronucleus assay. As a consequence, compound 5 was not further pursued.
Organizational Affiliation: 
Global Discovery Chemistry, Novartis Institutes for Biomedical Research, 4056 Basel, Switzerland. Electronic address: gebhard.thoma@novartis.com.